³ì³»Àå Ä¡·áÁ¦ ½ÃÀå : ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è¿Í Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® : ¾àÁ¦ Ŭ·¡½ºº°, ÀûÀÀÁõº°, À¯Åë ä³Îº°, Áö¿ªº°
Glaucoma Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Distribution Channel, and Geography
»óǰÄÚµå
:
1535259
¸®¼Ä¡»ç
:
The Insight Partners
¹ßÇàÀÏ
:
2024³â 07¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
³ì³»Àå Ä¡·áÁ¦ ½ÃÀåÀº 2023³â¿¡ 62¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2031³â¿¡´Â 80¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2023-2031³â CAGRÀº 3.2%·Î ÃßÁ¤µË´Ï´Ù.
½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ³ì³»Àå À¯º´·ü Áõ°¡, ³ì³»Àå¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ ¹× Á¶±â Áø´Ü, Á¦Ç° Ãâ½Ã Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª Åõ¾à °èȹ Áؼö ¹®Á¦¿Í ³ôÀº Ä¡·á ºñ¿ëÀ¸·Î ÀÎÇØ ³ì³»Àå Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
³ì³»Àå Ä¡·áÁ¦ ½ÃÀå µ¿Çâ :
³ì³»ÀåÀ̶ó´Â ¾ÈÁúȯÀº ÁÖ·Î ³ëÈ·Î ÀÎÇÑ ¾È¾Ð »ó½ÂÀ¸·Î ÀÎÇØ ½Ã½Å°æÀÌ ¼¼È÷ ¼Õ»óµÇ¾î °á±¹¿¡´Â µ¹ÀÌų ¼ö ¾ø´Â ½Ç¸í¿¡ ´ÞÇÒ ¼ö ÀÖ´Â ÁúȯÀÔ´Ï´Ù. ³ì³»ÀåÀÇ °¡Àå ÀϹÝÀûÀÎ Ä¡·á¹ý Áß Çϳª´Â ¾È¾àÀ» »ç¿ëÇÏ¿© ¾È¾ÐÀ» ³·Ãß´Â °ÍÀÔ´Ï´Ù. ±×·¯³ª ȯÀÚµéÀÇ ¾È¾à º¹¿ë ¼øÀÀµµ°¡ ³·°í, ȯÀÚ ±³À°ÀÌ ÃæºÐÇÏÁö ¾ÊÀ¸¸é Ä¡·áÀÇ ¼º°øÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾È¾Ð °ÇÏÁ¦´Â ±¹¼Ò ¹× Àü½Å ºÎÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, Ä¡·á¸¦ ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé ¼ö ÀÖ½À´Ï´Ù. ¾ÈÁ¤¼º Çâ»ó, ¼øÈ¯ ½Ã°£ ¿¬Àå, Ç¥Àû °áÇÕ Æ¯¼º µîÀ» °®Ãá °³·®Çü Á¦Á¦ ½ÃÀå °³Ã´¿¡ °ü½ÉÀÌ ÁýÁߵǰí ÀÖÀ¸¸ç, »õ·Î¿î Á¦Ç°ÀÌ ½ÃÀå¿¡ ÁøÀÔÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ÃÖ±Ù ³ì³»Àå Ä¡·áÁ¦ÀÇ ¹ßÀüÀº ½ÃÁß¿¡ ³ª¿Í ÀÖ´Â ³ì³»Àå Ä¡·áÁ¦¿¡ Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀûÀýÇÑ ±¸Á¶¿Í ¿ì¼öÇÑ °áÇÕ ´É·ÂÀ» °¡Áø ³ª³ëÀÔÀÚÀÇ »ç¿ëÀº ¾à¹°ÀÇ »ýü ÀÌ¿ë·ü°ú È¿´ÉÀ» ÃËÁøÇÕ´Ï´Ù. ¼¹æÇü(SR) ÀÓÇöõÆ® ¹× ±âŸ Çõ½ÅÀûÀÎ ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ±âÁ¸ Á¡¾ÈÁ¦ ´ëºñ ȯÀÚÀÇ ¼øÀÀµµ¸¦ °³¼±ÇÏ°í ºÎÀÛ¿ëÀ» °¨¼Ò½Ã۸ç, POAG Ä¡·áÀÇ À庮À» ±Øº¹ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¿©·¯ ȸ»ç°¡ ±¹¼Ò Åõ¿©¸¦ ´ëüÇÒ ¼ö ÀÖ´Â SR ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. 2022³â PubMed Central¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ POAG¿¡ ´ëÇØ ½ÂÀÎÇÑ À¯ÀÏÇÑ SR ¿ä¹ýÀº ¾Æ¶ó°£ÀÇ ºñ¸¶ÅäÇÁ·Î½ºÆ® SR(DurystaTM)ÀÔ´Ï´Ù. ºñ¸¶ÅäÇÁ·Î½ºÆ® ¾ÆÀ̸µ(Allergan), iDose(Glaukos Corporation), ENV515(Envisia Therapeutics), OTX-TP(Ocular Therapeutix), OTX-TIC(Ocular Therapeutix), ¶óŸ³ëÇÁ·Î½ºÆ® À¯¸®»ê SR(PolyActiva)À» Æ÷ÇÔÇÑ ´Ù¸¥ SR ¿ä¹ýÀº ÇöÀç ¿¬±¸ ÁßÀ̸ç, POAG °ü¸®¿¡¼ SR ¾à¹°Àü´Þ ±â¼úÀº Ä¡·á ÆÐ·¯´ÙÀÓÀ» ¹Ù²Ù°í Ä¡·á °á°ú¸¦ ȹ±âÀûÀ¸·Î °³¼±ÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. µû¶ó¼ »õ·Î¿î ¾à¹°Àü´Þ ¹æ¹ý°ú º´¿ë¿ä¹ýÀÇ °³¹ßÀº ³ì³»Àå Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä µ¿ÇâÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ºÎ¹®º° °³¿ä
³ì³»Àå Ä¡·áÁ¦ ½ÃÀåÀº ¾àǰ À¯Çüº°, ÀûÀÀÁõº°, À¯Åë ä³Îº°·Î ±¸ºÐµË´Ï´Ù.
¾à¹° À¯Çü¿¡ µû¶ó ½ÃÀåÀº º£Å¸ Â÷´ÜÁ¦, ¾ËÆÄ ¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦, ÇÁ·Î½ºÅ¸±Û¶õµò À¯»çü, ź»êÅ»¼öÈ¿¼Ò ¾ïÁ¦Á¦, º¹ÇÕÁ¦, ±âŸ·Î ³ª´µ¸ç, 2023³â¿¡´Â ÇÁ·Î½ºÅ¸±Û¶õµò À¯»çü ºÎ¹®ÀÌ ´õ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÁ·Î½ºÅ¸±Û¶õµò ¾Æ³¯·Î±×´Â ³ì³»Àå ȯÀÚÀÇ ¾È¾ÐÀÌ ³ôÀº °æ¿ì 1Â÷ ¼±Åà ġ·áÁ¦·Î »ç¿ëµË´Ï´Ù. ÇÁ·Î½ºÅ¸±Û¶õµò À¯»çü´Â 1ÀÏ 1ȸ Åõ¿©·Î ¾È¾ÐÀ» Å©°Ô ³·Ãß°í Àü½Å ºÎÀÛ¿ëÀÌ Àû½À´Ï´Ù. µû¶ó¼ ÇÁ·Î½ºÅ¸±Û¶õµò À¯»çüÀÇ ÀåÁ¡Àº ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð È®´ëÀÇ ¿øÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
½ÃÀåÀº ÀûÀÀÁõ¿¡ µû¶ó °³¹æ°¢ ³ì³»Àå, Æó¼â°¢ ³ì³»Àå, ±âŸ·Î ºÐ·ùµË´Ï´Ù. °³¹æ°¢ ³ì³»Àå ºÎ¹®Àº 2023³â¿¡ °¡Àå Å« ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2031³â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °³¹æ°¢ ³ì³»ÀåÀº ³ì³»ÀåÀÇ °¡Àå ÈçÇÑ ÇüÅÂÀ̸ç, ¾à 95%ÀÇ »ç¶÷µéÀÌ ÀÌ ÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. óÀ½¿¡´Â ¾Æ¹«·± Áõ»óÀÌ ³ªÅ¸³ªÁö ¾Ê½À´Ï´Ù. ±×·¯³ª ¾î´À ½ÃÁ¡¿¡ À̸£¸é Ä¡·áÇÏÁö ¾ÊÀ¸¸é Ãø¸é(ÁÖº¯ºÎ) ½Ã¾ß¸¦ Àұ⠽ÃÀÛÇÏ¿© ½Ç¸í¿¡ ´ÞÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀåÀº À¯Åë ä³Îº°·Î º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹À¸·Î ±¸ºÐµÇ¸ç, 2023³â¿¡´Â º´¿ø ¾à±¹ ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³ì³»Àå Ä¡·áÁ¦ ½ÃÀå Áö¿ªÀû °³¿ä
³ì³»Àå Ä¡·áÁ¦ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ), À¯·´(½ºÆäÀÎ, ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Çѱ¹, Áß±¹, Àεµ, ÀϺ», È£ÁÖ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(³²¾ÆÇÁ¸®Ä«, »ç¿ìµð¾Æ¶óºñ¾Æ, ¾Æ¶ø¿¡¹Ì¸®Æ®, ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«), Áß³²¹Ì(ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì)¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù. ¾Æ¶ø¿¡¹Ì¸®Æ®, ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«), Áß³²¹Ì(ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì)ÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº 2023-2031³â °¡Àå ºü¸¥ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ¼ºÀå¿¡´Â »õ·Î¿î ³ì³»Àå Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ ÁøÇà ÁßÀÎ ÀÓ»ó ¿¬±¸¿Í ÀÌ Áö¿ªÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡ µîÀÇ ¿äÀÎÀÌ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â 2023³â ¸ÅÃâ¾× ±âÁØÀ¸·Î °¡Àå Å« ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå °³¿ä
Á¦3Àå Á¶»ç ¹æ¹ý
2Â÷ Á¶»ç
1Â÷ Á¶»ç
°¡¼³ Ã¥Á¤
°Å½Ã°æÁ¦ ¿äÀÎ ºÐ¼®
±âÃÊ ¼öÄ¡ ÀÛ¼º
µ¥ÀÌÅÍ »ï°¢Ãø·®
±¹°¡ ·¹º§ µ¥ÀÌÅÍ
Á¦4Àå ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ±¸µµ
Á¦5Àå ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
³ì³»Àå Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
³ì³»Àå ÀÌȯÀ²ÀÇ Áõ°¡
Á¦Ç° Ãâ½Ã, Á¦ÈÞ, ÀμöÀÇ Áõ°¡
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ±âȸ
ÇâÈÄ µ¿Çâ
»õ·Î¿î ¾à¹°Àü´Þ ¹æ¹ýÀÇ °³¹ß
ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ
Á¦6Àå ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®
³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ¸ÅÃâ, 2021-2031³â
³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ¿¹Ãø ºÐ¼®
Á¦7Àå ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ºÐ¼® - ¾àÁ¦ Ŭ·¡½ºº°
¥â Â÷´Ü¾à
¥á ¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦
Prostaglandins Analogues
ź»êÅ»¼ö¼ÒÈ¿¼Ò ÀúÇØÁ¦
º´¿ë¾à
±âŸ
Á¦8Àå ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ºÐ¼® - ÀûÀÀÁõº°
°³¹æ°¢ ³ì³»Àå
Æó¼â ¿ì°¢ ³ì³»Àå
±âŸ
Á¦9Àå ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ºÐ¼® - À¯Åë ä³Îº°
º´¿ø ¾à±¹
¼Ò¸Å ¾à±¹
¿Â¶óÀÎ ¾à±¹
Á¦10Àå ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå - Áö¿ª ºÐ¼®
ºÏ¹Ì
À¯·´
µ¶ÀÏ
ÇÁ¶û½º
¿µ±¹
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
Áß±¹
ÀϺ»
Àεµ
È£ÁÖ
Çѱ¹
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±âŸ ±¹°¡
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
»ç¿ìµð¾Æ¶óºñ¾Æ
³²¾ÆÇÁ¸®Ä«°øÈ±¹
¾Æ¶ø¿¡¹Ì¸®Æ®
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áß³²¹Ì
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
±âŸ Áß³²¹Ì
Á¦11Àå ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå - ¾÷°è »óȲ
³ì³»Àå Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå Àü·«
À¯±âÀû ¼ºÀå Àü·«
¹«±âÀû ¼ºÀå Àü·«
Á¦12Àå ±â¾÷ °³¿ä
Alcon AG
AbbVie Inc
Bausch & Lomb Inc
Fera Pharmaceuticals, LLC
Viatris Inc
Novartis AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Thea Pharma Inc
Santen Pharmaceutical Co., Ltd.
Á¦13Àå ºÎ·Ï
KSA
¿µ¹® ¸ñÂ÷
The glaucoma therapeutics market was valued at US$ 6.24 billion in 2023 and is expected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031.
Key factors driving the market growth are the growing prevalence of glaucoma, rising awareness and early diagnosis of the disease, and increasing product launches are expected to drive the market growth. However, compliance issues with medication regimens and the high cost of treatments hinder the glaucoma therapeutics market growth.
Market Trends of the Glaucoma Therapeutics Market:
The gradual damage of the optic nerve-typically associated with high pressure inside the eye (intraocular pressure)-predominantly due to aging can lead to a group of eye diseases called Glaucoma, which can eventually result in irreversible blindness. One of the most common treatments for glaucoma is to reduce intraocular pressure by using eye drops. However, patient adherence to these eye drops can be challenging, and inadequate patient education can impede treatment success. Additionally, ocular hypotensive drugs can cause local and systemic side effects that may further complicate the treatment. Rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market. Recent advancements in glaucoma therapeutics have revolutionized the available treatments in the market. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the bioavailability and efficacy of the drug. Sustained-release (SR) implants and other innovative drug delivery systems offer improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers in treating POAG. As per the article published in PubMed Central in 2022, the only approved SR therapy for POAG by the Food and Drug Administration (FDA) is Bimatoprost SR (DurystaTM) from Allergan plc. Other SR therapies including bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods and combination therapies is likely to remain a key trend in the glaucoma therapeutics market.
Glaucoma therapeutics Market: Segmental Overview
The glaucoma therapeutics market is segmented on the basis of drug class, indication, and distribution channel.
By drug class, the market is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023. Prostaglandin analogs are the first-line treatment for high intraocular pressure in glaucoma patients. They offer a once-a-day dosing, a significant reduction in intraocular pressure, and low systemic side effects. Thus, the benefits of prostaglandin analogs are responsible for the expansion of the glaucoma therapeutics market size.
The market, by indication, is segmented into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest glaucoma therapeutics market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. Open-angle glaucoma is the most common form of glaucoma, which affects approximately 95% of individuals. Initially, it does not show any symptoms. However, at some point, an individual may start losing their side (peripheral) vision without treatment, resulting in total blindness.
By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023.
Glaucoma therapeutics Market: Geographical Overview
The scope of the glaucoma therapeutics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the market from 2023 to 2031. Factors such as ongoing clinical studies for developing novel glaucoma therapies, as well as increasing healthcare expenditures in the region, contribute to the glaucoma therapeutics market growth in Asia Pacific. In terms of revenue, North America accounted for the largest glaucoma therapeutics market share in 2023.
Table Of Contents
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Glaucoma Therapeutics Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Glaucoma Therapeutics Market - Key Market Dynamics
5.1 Glaucoma Therapeutics Market - Key Market Dynamics
5.2 Market Drivers
5.2.1 Mounting Incidence of Glaucoma Disease
5.2.2 Increasing Number of Product Launches, Collaborations, Acquisitions
5.3 Market Restraints
5.3.1 Medication Regimen Compliance Issues
5.4 Market Opportunities
5.4.1 Development of Wearable Technologies
5.5 Future Trends
5.5.1 Development of Novel Drug Delivery Methods
5.6 Impact of Drivers and Restraints:
6. Glaucoma Therapeutics Market - Global Market Analysis
6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
6.2 Glaucoma Therapeutics Market Forecast Analysis
7. Glaucoma Therapeutics Market Analysis - by Drug Class
7.1 Beta Blockers
7.1.1 Overview
7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Alpha Adrenergic Agonists
7.2.1 Overview
7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Prostaglandins Analogues
7.3.1 Overview
7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Carbonic Anhydrase Inhibitors
7.4.1 Overview
7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Combination Drugs
7.5.1 Overview
7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8. Glaucoma Therapeutics Market Analysis - by Indication
8.1 Open Angle Glaucoma
8.1.1 Overview
8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Angle Closure Glaucoma
8.2.1 Overview
8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9. Glaucoma Therapeutics Market Analysis - by Distribution Channel
9.1 Hospital Pharmacy
9.1.1 Overview
9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Retail Pharmacy
9.2.1 Overview
9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Online Pharmacy
9.3.1 Overview
9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10. Glaucoma Therapeutics Market - Geographical Analysis
10.1 Overview
10.2 North America
10.2.1 North America Glaucoma Therapeutics Market Overview
10.2.2 North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.2.3 North America: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.2.3.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
10.2.4 North America: Glaucoma Therapeutics Market Breakdown, by Indication
10.2.4.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
10.2.5 North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.2.5.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
10.2.6 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.2.6.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.2.6.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.2.6.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.2.6.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
10.2.6.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.2.6.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.2.6.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.2.6.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
10.2.6.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.2.6.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.2.6.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.2.6.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
10.2.6.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3 Europe
10.3.1 Europe Glaucoma Therapeutics Market Overview
10.3.2 Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.3.3 Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.3.3.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
10.3.4 Europe: Glaucoma Therapeutics Market Breakdown, by Indication
10.3.4.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
10.3.5 Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3.5.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
10.3.6 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.3.6.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.3.6.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.3.6.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.3.6.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
10.3.6.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3.6.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.3.6.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.3.6.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
10.3.6.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3.6.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.3.6.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.3.6.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
10.3.6.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3.6.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.3.6.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.3.6.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
10.3.6.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3.6.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.3.6.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.3.6.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
10.3.6.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3.6.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.3.6.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.3.6.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
10.3.6.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4 Asia Pacific
10.4.1 Asia Pacific Glaucoma Therapeutics Market Overview
10.4.2 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.4.3 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.4.3.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
10.4.4 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication
10.4.4.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
10.4.5 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4.5.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
10.4.6 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.4.6.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.4.6.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.4.6.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.4.6.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
10.4.6.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4.6.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.4.6.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.4.6.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
10.4.6.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4.6.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.4.6.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.4.6.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
10.4.6.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4.6.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.4.6.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.4.6.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
10.4.6.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4.6.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.4.6.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.4.6.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
10.4.6.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4.6.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.4.6.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.4.6.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
10.4.6.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.5 Middle East and Africa
10.5.1 Middle East and Africa Glaucoma Therapeutics Market Overview
10.5.2 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.5.3 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.5.3.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
10.5.4 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
10.5.4.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
10.5.5 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.5.5.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
10.5.6 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.5.6.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.5.6.2 Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.5.6.2.1 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.5.6.2.2 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Indication
10.5.6.2.3 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.5.6.3 South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.5.6.3.1 South Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.5.6.3.2 South Africa: Glaucoma Therapeutics Market Breakdown, by Indication
10.5.6.3.3 South Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.5.6.4 United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.5.6.4.1 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.5.6.4.2 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Indication
10.5.6.4.3 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.5.6.5 Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.5.6.5.1 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.5.6.5.2 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
10.5.6.5.3 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.6 South and Central America
10.6.1 South and Central America Glaucoma Therapeutics Market Overview
10.6.2 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.6.3 South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.6.3.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
10.6.4 South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
10.6.4.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
10.6.5 South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.6.5.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
10.6.6 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.6.6.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
10.6.6.2 Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.6.6.2.1 Brazil: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.6.6.2.2 Brazil: Glaucoma Therapeutics Market Breakdown, by Indication
10.6.6.2.3 Brazil: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.6.6.3 Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.6.6.3.1 Argentina: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.6.6.3.2 Argentina: Glaucoma Therapeutics Market Breakdown, by Indication
10.6.6.3.3 Argentina: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.6.6.4 Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10.6.6.4.1 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
10.6.6.4.2 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
10.6.6.4.3 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
11. Glaucoma Therapeutics Market - Industry Landscape
11.1 Growth Strategies in Glaucoma Therapeutics Market
11.2 Organic Growth Strategies
11.3 Inorganic Growth Strategies
12. Company Profiles
12.1 Alcon AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 AbbVie Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Bausch & Lomb Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Fera Pharmaceuticals, LLC
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Viatris Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Novartis AG
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Sun Pharmaceutical Industries Ltd
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Teva Pharmaceutical Industries Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Thea Pharma Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Santen Pharmaceutical Co., Ltd.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
°ü·ÃÀÚ·á